Clinical Trials in Seattle

Showing 4481-4500 of 7,135 trials

Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

NCT02092909

Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 90% of the patients with Waldenström's macroglobulinemia. MYD88 is a key linker protein in the signaling pathway of Toll Like Receptors (TLRs) 7, 8, and 9, and IMO-8400 is an oligonucleotide specifically designed to inhibit TLRs 7,8, and 9. The scientific hypothesis for use of IMO-8400 to treat patients with Waldenström's macroglobulinemia depends on the inhibition of mutant MYD88 signaling in the TLR pathway, thereby interrupting the proliferation of cell populations responsible for the propagation of the disease.

Waldenstrom's Macroglobulinemia

Idera Pharmaceuticals, Inc.31 participantsStarted Mar 2014

Fayetteville, Arkansas, United States • Los Angeles, California, United States • Jacksonville, Florida, United States +7 more locations

WITHDRAWNPhase 2< 1 mile

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

NCT03397186

This research trial studies the immune changes following trabectedin in patients with sarcoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Analyzing tumor tissue may help to understand the changes in immune cells in or around the tumor or if there is an increase in immune cells in the tumor after receiving trabectedin.

Myxoid LiposarcomaRound Cell LiposarcomaStage III Soft Tissue Sarcoma AJCC v7+3 more

Fred Hutchinson Cancer CenterStarted Jun 2018

Seattle, Washington, United States

Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

Find Trials by Condition in Seattle

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Structured Treatment of Pain (STOP) Study

Synchronized Immunization NotifiCations

Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

The Effect of Primary Care Opioid Taper Plans on Sustained Opioid Taper

One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease

Post-Mastectomy Surveillance to Detect Recurrence in Breast Cancer Patients

The Prone Breast Radiation Therapy Trial

An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy

A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer